Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision deficits and blindness, especially with the development of diabetic macular edema (DME). The DME market became more competitive with the launch of vascular endothelial growth factor (VEGF) inhibitors—approved agents Eylea and Lucentis—which are the standards of care for center-involved DME. Ozurdex and Iluvien, both long-acting corticosteroid implants, are also approved for DME in some markets. Of note, Lucentis 0.3 mg (0.5 mg in Europe) and Eylea are now both approved for DR without DME. Factoring in the near-term launch of biosimilars of Lucentis 0.5 mg and Eylea, growing clinical data supporting the treatment of some DR patients without DME with pharmacotherapies, and a dynamic development pipeline, competition is expected to increase in this space.

QUESTIONS ANSWERED

  • How large is the treatable DR / DME population and how will diagnosis / drug-treatment rates change over time?
  • Do KOLs perceive any differences between Avastin, Eylea, and Lucentis? How is the use of these drugs expected to change over the next ten years as emerging therapies enter the market? How are Iluvien and Ozurdex being used to treat DME?
  • How will market dynamics be impacted by the launch of biosimilars of Lucentis 0.5 mg and Eylea?
  • How have Lucentis and Eylea been incorporated into the treatment algorithm for DR exclusive of DME in the United States? What would be the impact of Novartis’s brolucizumab if it is successfully launched for DME and PDR?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading retinal specialists and supported by survey data collected for this and other DRG research.

Epidemiology: Prevalence of severe NPDR, PDR, and DME, by country, including diagnosed/drug-treated populations.

Forecast: Ten-year, annualized, drug-level sales and patient share of key DR and DME therapies through 2029, segmented by brands/biosimilars and epidemiological subpopulations.

Emerging therapies:  Phase III/PR: 3 drugs; Phase II: 7 drugs; coverage of select earlier phase products.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Updates
      • April 2020
      • March 2020
    • Market Outlook
      • Key Findings
        • Market Overview
      • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for DR/DME?
        • What Factors Are Constraining the Market for DR/DME?
      • Drug-Class-Specific Trends
        • VEGF Inhibitors
        • Corticosteroid Implants
        • VEGF/Ang-2 Inhibitors
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Etiology
      • Pathophysiology
        • Disease Classification
        • Pathogenesis
      • Key Pathways and Drug Targets
      • Disease Overview
    • Epidemiology
      • Key findings
        • Expert Insights
        • Note About Our Epidemiology Populations
      • Epidemiology Populations
        • Total Prevalent Cases of DME
        • Diagnosed and Drug-Treated Cases of DME
        • Total Prevalent Cases of Diabetic Retinopathy by Severity
        • Diagnosed and Drug-Treated Cases of Diabetic Retinopathy by Severity
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • VEGF Inhibitors
        • Corticosteroid Implants
        • Corticosteroid Injections
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in DR/DME
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • VEGF Inhibitors
        • VEGF / Ang-2 Inhibitors
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Market Forecast Assumptions File
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
    • Appendix
      • DR / DME Bibliography

Author(s): Natalie Taylor, PhD; Emma McFadden, PhD; Himanshu Jain, M.S. Pharm; Fjoralba Kristo, MD, MPH; Ruchita Kumar, Ph.D

Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.

Emma McFadden, is a  Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and ; Prior to joining Decision Resources Group, Emma earned a in neuroscience and a in biochemistry from Trinity College Dublin.  

Himanshu joined the CNS / ophthalmology team at Decision Resources Group in 2016. He has authored content for psychiatry and ophthalmology (retinal / nonretinal) indications, including schizophrenia, age-related macular degeneration, diabetic retinopathy / diabetic macular edema, dry eye disease, glaucoma, and uveitis. Himanshu has more than ten years of experience working in market research and consulting firms, and has managed multiple market assessment projects, including bottom-up forecasts, across multiple therapy areas. He holds a degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.

Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods. Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.

Ruchita has joined as a Lead Analyst in the Central Nervous System and Ophthalmology team at Decision Resources Group. She comes with eight years of experience in handling various types of commercial assessment projects. She has worked on variety of opportunity assessment and market intelligence projects involving preparation of disease narratives, epi-based forecasts, patent landscapes, social media analysis and building brand performance reports across different therapy areas. She earned a in design and development of modified release dosage forms of anti-diabetic drugs from the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh.


Related Reports

Diabetic Macular Edema / Diabetic Retinopathy | Current Treatment | Detailed, Expanded Analysis (US)

Patients with diabetic retinopathy (DR) experience retinal damage that can lead to vision impairment and eventual blindness, especially with the developm...

View Details

Diabetic Macular Edema | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key diabetic macular edema...

View Details

Diabetic Retinopathy | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key diabetic retinopathy&n...

View Details